News >

STORM Data Show Encouraging Responses, OS With Selinexor/Dexamethasone in Penta-Refractory Myeloma

Jason Harris
Published: Saturday, Sep 15, 2018

Sundar Jagannath, MD

Sundar Jagannath, MD
Results of the phase IIb STORM trial demonstrated that the combination of selinexor and dexamethasone demonstrated promising clinical activity in patients with penta-refractory multiple myeloma, a population that currently has no standard-of-care regimen.1 


  1. Jagannath J, Vogl DT, Dimopoulos MA, et al. Phase 2b results of the STORM study: oral selinexor plus low dose dexamethasone (sd) in patients with penta-refractory myeloma (penta-MM). Clin Lymphoma Myeloma Leuk. 2018;18(suppl; Abstract MM-255). doi: 10.1016/j.clml.2018.07.149.
  2. Vogl DT, Dingli D, Cornell RF, et al. Selinexor and low dose dexamethasone (Sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-CD38 Ab refractory multiple myeloma (MM): STORM study. Presented at: 2018 ASH Annual Meeting; December 3-6, 2016; San Diego, California. Abstract 491.
  3. Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(9):859-866. doi: 10.1200/JCO.2017.75.5207.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication